Thursday, April 11, 2019, Anaheim, California, 12:15 PM – 1:45 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from Practice — A 6-Part CNE Symposia Series Held During the ONS 44th Annual Congress

PART 4 — Chronic Lymphocytic Leukemia

Location:
Anaheim Marriott
700 West Convention Way
Anaheim, CA 92802
Hotel Phone: (714) 750-8000

Meeting Room:
Grand Ballroom E-K (Lobby Level)
Schedule:
11:45 AM – 12:15 PM
Registration and Lunch Buffet

12:15 PM – 1:45 PM
Educational Program
 
There is no registration fee for this event. Preregistration is highly recommended as seating and meal service are limited.

Faculty:
Paul M Barr, MD
Medical Director, Clinical Trials Office
Associate Professor of Medicine
Wilmot Cancer Institute
University of Rochester Medical Center
Rochester, New York

Josie Bazemore, MSN, AGPCNP-BC
Dana-Farber Cancer Institute
Boston, Massachusetts

Nitin Jain, MD
Associate Professor of Medicine
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Lynn Rich, RN, MSN, OCN, BC-ANP
University of Rochester
Wilmot Cancer Institute
Lymphoma Program
Rochester, New York

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida
 
Meeting space has been assigned to provide a symposium supported by AbbVie Inc, Genentech, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC and Pharmacyclics LLC, an AbbVie Company during the Oncology Nursing Society’s (ONS) 44th Annual Congress, April 11-14, 2019 in Anaheim, California. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
11:45 AM – 12:15 PM – Registration and Lunch Buffet
12:15 PM – 1:45 PM – Educational Program

Cases Presented Will Include Discussion of the Following Topics:

  • Initial workup and risk assessment for patients with chronic lymphocytic leukemia (CLL)
  • Available and emerging data guiding therapeutic selection for younger and older patients with newly diagnosed disease
  • Contemporary management of relapsed/refractory CLL
  • Emerging research information on novel BTK inhibitors in the management of CLL
  • Other novel agents and strategies under investigation for CLL
A detailed agenda will be available in the coming weeks

Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of chronic lymphocytic leukemia (CLL).

Learning Objectives and Goals:
Upon completion of this activity, participants should be able to:

  • Provide patient education to enhance clinical decision-making regarding systemic agents available for the management of chronic lymphocytic leukemia (CLL).
  • Appreciate the contribution of patient performance status and comorbidities, biomarker profile and prior therapeutic exposure to the selection and sequencing of systemic therapy for newly diagnosed and relapsed/refractory CLL.
  • Design and implement a plan of care to recognize and manage side effects and toxicities associated with existing and recently approved systemic therapies for patients with CLL to support quality of life and continuation of therapy.
  • Appreciate available data with and consider the potential clinical roles of novel agents and regimens that may soon provide patients with treatment options beyond the initial indications.
  • Recall available and emerging data with other investigational agents, regimens and immunotherapeutic strategies currently in Phase III testing for CLL, and, where applicable, refer eligible patients for clinical trial participation or expanded access programs.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with CLL to optimize clinical and quality-of-life outcomes.
Accreditation Statement:
Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements:
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information:
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures:
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP CME/CNE planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

Supporters:
This activity is supported by educational grants from AbbVie Inc, Genentech, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC and Pharmacyclics LLC, an AbbVie Company.

Anaheim Marriott
700 West Convention Way
Anaheim, CA 92802
Hotel Phone: (714) 750-8000

Meeting Room: 
Grand Ballroom E-K (Lobby Level)

The Anaheim Marriott is the headquarters hotel for the 2019 ONS Congress and is conveniently located near the Anaheim Convention Center (0.2 miles).

 

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of chronic lymphocytic leukemia.

There is no registration fee for this event. However, preregistration is highly recommended as seating is limited.

Registration for clinicians in practice

• I am a practicing nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Standby registration for nonclinicians/industry professionals*

For all other professionals, we are unable to confirm seating at this time. If you would like to stand by for participation in this event, please provide your contact information. Should seats become available for the program, we will notify you.

Standby registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CNE programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.